Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Yong-Chen Lu"'
Publikováno v:
Cancer Immunol Res
Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) can mediate responses in some patients with metastatic epithelial cancer. Identifying gene signatures associated with successful ACT might enable the development of improved thera
Autor:
Jared J. Gartner, Yong-Chen Lu, Paul F. Robbins, Steven A. Rosenberg, Frank J. Lowery, Todd D. Prickett, Zhili Zheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundRecognition of neoantigens by T cells plays a major role in cancer immunotherapy. Identification of neoantigen-specific T-cell receptors (TCRs) has become a critical research tool for studying T cell-mediated responses after immunotherapy.
Autor:
Anna Pasetto, Yong-Chen Lu
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
T cells have been known to be the driving force for immune response and cancer immunotherapy. Recent advances on single-cell sequencing techniques have empowered scientists to discover new biology at the single-cell level. Here, we review the single-
Autor:
Lori McIntyre, Yong-Chen Lu, Liqiang Xi, Richard A. Morgan, Steven A. Feldman, Stephanie L. Goff, Parisa Malekzadeh, Lily Lu, Howard A. Fine, Richard M. Sherry, Nicholas P. Restifo, Monica Epstein, Zhili Zheng, Paul F. Robbins, Mark Raffeld, James Chih-Hsin Yang, Steven A. Rosenberg
Publikováno v:
J Immunother
A deletion variant of epidermal growth factor receptor (EGFRvIII) is a known driver mutation in a subset of primary and secondary glioblastoma multiforme. Adoptive transfer of genetically modified chimeric-antigen receptor (CAR) lymphocytes has demon
Autor:
Harshini Chinnasamy, Todd D. Prickett, Li Jia, Paul F. Robbins, Isaac R. Kriley, Yasmine Assadipour, Steven A. Rosenberg, Steven A. Feldman, Stephanie L. Goff, Jared J. Gartner, Nikolaos Zacharakis, Jessica S. Crystal, John R. Wunderlich, Yong-Chen Lu, Robert Somerville, Mary A. Black, Lily Lu, Hui Xu, Zhili Zheng
Publikováno v:
Clinical Cancer Research. 23:4347-4353
Purpose: The administration of autologous tumor-infiltrating lymphocytes (TILs) can mediate durable tumor regressions in patients with melanoma likely based on the recognition of immunogenic somatic mutations expressed by the cancer. There are limite
Autor:
Todd D. Prickett, Eric Tran, Anna Pasetto, Scott Kivitz, Steven A. Rosenberg, Paul F. Robbins, Drew C. Deniger, Parisa Malekzadeh, Isaac R. Kriley, Yong-Chen Lu, Maria R. Parkhurst, David S. Schrump, Satyajit Ray, Winifred Lo, Jared J. Gartner, Biman C. Paria, Li Jia, Thomas E. Shelton
Adoptive cell therapy (ACT) with T cells targeting neoantigens can mediate durable responses in patients with metastatic cancer. Cell therapies targeting common shared antigens for epithelial cancers are not yet broadly available. Here, we report the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::545b9e388fee4a1d712a26bafe68f5c0
https://europepmc.org/articles/PMC6685528/
https://europepmc.org/articles/PMC6685528/
Autor:
Yong-Chen Lu, Paul F. Robbins
Publikováno v:
International Immunology. 28:365-370
Studies first carried out in the 1980s have demonstrated murine T cells can recognize mutated gene products, known as neoantigens, and that these T cells are capable of mediating tumor rejection. The first human tumor antigens isolated in the early 1
Autor:
Yong-Chen Lu, Paul F. Robbins
Publikováno v:
Seminars in Immunology. 28(1):22-27
Neoantigens are antigens that are encoded by tumor-specific mutated genes. Studies in the past few years have suggested a key role for neoantigens in cancer immunotherapy. Here we review the discoveries of neoantigens in the past two decades and the
Autor:
Anna Pasetto, Zhili Zheng, Paul F. Robbins, Jared J. Gartner, Steven A. Feldman, Harshini Chinnasamy, Michelle M. Langhan, Stephanie L. Goff, Nikolaos Zacharakis, Li Jia, Yong-Chen Lu, Steven A. Rosenberg, Katarzyna Trebska-McGowan, Todd D. Prickett, Hui Xu, Robert Somerville, Mary A. Black, Thomas E. Shelton
Immunotherapy using either checkpoint blockade or the adoptive transfer of antitumor lymphocytes has shown effectiveness in treating cancers with high levels of somatic mutations—such as melanoma, smoking-induced lung cancers and bladder cancer—w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbc31464c573e58f95d626fcf15186b8
https://europepmc.org/articles/PMC6348479/
https://europepmc.org/articles/PMC6348479/
Autor:
Linda L. Parker, Richard M. Sherry, Steven A. Rosenberg, Yong-Chen Lu, Christopher A. Klebanoff, Stephanie L. Goff, Zhili Zheng, Udai S. Kammula, Mary Ann Toomey, Xin Yao, Steven A. Feldman, Paul F. Robbins, Donald E. White, Yong F. Li, James Chih-Hsin Yang, Pierre van der Bruggen, Tangying Lu
Purpose Adoptive transfer of genetically modified T cells is being explored as a treatment for patients with metastatic cancer. Most current strategies use genes that encode major histocompatibility complex (MHC) class I–restricted T-cell receptors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a29796472156108031793a302320dd0
https://europepmc.org/articles/PMC5652397/
https://europepmc.org/articles/PMC5652397/